Zafgen Reports First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Canaccord Genuity Maintain Buy Following Zafgen (ZFGN) Q1 Results
May 13, 2015 10:44 AM EDTCanaccord Genuity maintain a Buy rating on Zafgen (NASDAQ: ZFGN), and lowered the price target to $53.00 (from $58.00), following Q1 results. Zafgen reported Q1 EPS of ($0.53), beating Canaccord's estimate of ($0.62) by $0.09. During the last earnings call, it was announced that data from the Ph3 Prader-Willi Syndrom (PWS) trial would be delayed until 2Q16.... More
Zafgen (ZFGN) Tops Q1 EPS by 5c
May 12, 2015 4:10 PM EDTZafgen (NASDAQ: ZFGN) reported Q1 EPS of ($0.53), $0.05 better than the analyst estimate of ($0.58).
The company ended the quarter with cash and cash equivalents and marketable securities totaling $234.2 million.
"We are very pleased with our accomplishments for the first quarter of 2015. We are thrilled to have seen a high rate of enrollment at our most recently-opened bestPWS clinical trial sites, which will enable us to release six month data... More
